# Test Results: writing/specific-aims.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** writing/specific-aims.md
- **Model:** claude-sonnet-4.6
- **Model ID (pinned):** claude-sonnet-4-6
- **Endpoint:** native
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I am drafting a Specific Aims page for an NIH R21 (exploratory/developmental) on microbiome biomarkers for colorectal cancer screening. The funding agency emphasizes innovative approaches and high-risk/high-reward research.

My research plan notes:

Problem: Colorectal cancer is the 2nd leading cause of cancer death in the US. Colonoscopy screening is effective but has low compliance (~60%). Non-invasive biomarkers could improve screening rates. Current fecal tests (FIT, Cologuard) have limited sensitivity for adenomas.

My approach: Develop a microbiome-based classifier that detects precancerous adenomas from stool samples. Leverage the known microbiome changes in CRC to detect disease earlier.

Preliminary data:
- Pilot study with 25 adenoma cases, 25 controls
- 16S sequencing identified 12 differentially abundant taxa
- Random forest classifier achieved 78% AUC (needs validation)

Aim 1: Validate and refine the microbiome classifier in an independent cohort
- Partner with GI clinic for prospective sample collection
- Target 100 adenoma cases, 100 controls
- Test classifier performance and refine features

Aim 2: Integrate microbiome data with existing biomarkers (FIT)
- Hypothesis: combined model outperforms either alone
- Collect FIT results alongside microbiome samples
- Build integrated classifier

Innovation: First study to combine microbiome signatures with established screening biomarkers for adenoma detection

My lab: expertise in microbiome bioinformatics, machine learning, established GI collaborations

Target length: 1 page (R21 limit)

Task: Draft a Specific Aims page with the following structure:

**Opening paragraph (The Hook):**
- First sentence: Establish the problem and its significance (the "so what")
- Knowledge gap: What critical barrier limits progress?
- Your solution: How does your approach address this gap?
- Long-term goal and overall objective for this proposal

**Specific Aims (2-3 typically):**
For each aim:
- State the aim as a clear objective (what you will do)
- Brief rationale (why this aim matters)
- Approach summary (1-2 sentences on how)
- Expected outcome (what you'll learn)

**Closing paragraph:**
- How the aims integrate and build on each other
- Impact statement: what will be possible after this work that isn't possible now?
- Connection to agency mission (if applicable)

Constraints:
- Use ONLY information from my notes—do not fabricate preliminary data, citations, or capabilities
- Flag any claims that need preliminary data support as [NEEDS PRELIM DATA]
- Flag any citations needed as [CITE]
- Keep within target length
- Use active, confident language—avoid excessive hedging
- Make aims concrete and achievable within the funding period

Output format: Formatted aims page with section headers. Flag gaps for my attention.
````

## Model Output
````
# Specific Aims

Colorectal cancer (CRC) is the second leading cause of cancer death in the United States, yet it is largely preventable through early detection of precancerous adenomas [CITE: CRC incidence/mortality statistics]. The central barrier to prevention is not biology—it is compliance. Despite the proven efficacy of colonoscopy, only ~60% of eligible adults undergo screening [CITE: screening compliance data], leaving millions at undetected risk. Current non-invasive alternatives, including fecal immunochemical testing (FIT) and multi-target stool DNA testing (Cologuard), have limited sensitivity for adenomas—the critical window for intervention—creating an urgent need for more accurate, non-invasive screening tools [CITE: FIT/Cologuard sensitivity data for adenomas]. The gut microbiome undergoes measurable compositional shifts during CRC development [CITE: foundational microbiome-CRC studies], offering an underexplored biological signal that could be harnessed for earlier detection. Our **long-term goal** is to develop a validated, non-invasive microbiome-based screening tool that improves adenoma detection and increases screening uptake. The **overall objective of this proposal** is to validate a stool microbiome classifier for adenoma detection and determine whether integrating microbiome signatures with FIT results produces a superior combined diagnostic model. Our pilot data in 50 participants (25 adenoma cases, 25 controls) identified 12 differentially abundant taxa and yielded a random forest classifier with 78% AUC, establishing proof-of-concept and providing the foundation for the following aims.

---

## Aim 1: Validate and refine the stool microbiome classifier for adenoma detection in an independent prospective cohort.

**Rationale:** A classifier trained on 50 participants requires independent validation before its clinical utility can be assessed. Prospective collection in a real-world GI clinic setting will test generalizability and identify the most robust microbial features for adenoma detection.

**Approach:** We will prospectively enroll 100 adenoma cases and 100 colonoscopy-confirmed controls through our established GI clinic partnership. Stool samples will undergo 16S rRNA sequencing, and the existing classifier will be tested in this held-out cohort. We will then apply feature selection and model refinement to optimize classifier performance. [NEEDS PRELIM DATA: Power/sample size justification for 100/100 target—recommend adding sensitivity analysis showing this N is sufficient to detect a meaningful AUC improvement over baseline]

**Expected Outcome:** A validated, refined microbiome classifier with defined sensitivity, specificity, and AUC in an independent cohort, along with a prioritized set of microbial features for integration in Aim 2.

---

## Aim 2: Determine whether integrating the microbiome classifier with FIT improves adenoma detection accuracy beyond either biomarker alone.

**Rationale:** FIT and microbiome signatures likely capture complementary biological signals—host-derived blood loss and microbial dysbiosis, respectively. A combined model may overcome the sensitivity limitations of each test individually, representing a clinically actionable advance. [NEEDS PRELIM DATA: Any pilot data or published evidence suggesting FIT and microbiome signals are non-redundant would strengthen this rationale—flag for literature review or add to pilot if feasible]

**Approach:** FIT results will be collected concurrently with stool microbiome samples from the Aim 1 cohort, enabling direct comparison within the same participants. We will build an integrated classifier combining microbiome features and FIT scores using machine learning approaches established in our lab, benchmarked against each biomarker alone using cross-validated AUC.

**Expected Outcome:** Quantification of the additive diagnostic value of combining microbiome and FIT data, and a prototype integrated classifier ready for larger-scale validation. If the combined model does not outperform FIT alone, this negative result will itself provide critical guidance for the field. [NOTE: Framing the null result as informative is appropriate for R21 high-risk/high-reward framing]

---

## Integration and Impact

These aims are deliberately sequential and mutually reinforcing: Aim 1 produces a validated classifier and a well-characterized cohort with concurrent FIT data, which Aim 2 directly leverages to build and test the integrated model. Together, they transform a promising pilot signal into a rigorously validated, multi-marker diagnostic framework. **Upon completion, this work will establish—for the first time—whether microbiome signatures provide independent and additive value over existing standard-of-care screening tests for adenoma detection.** This positions our team to pursue R01-level validation in larger, diverse populations and to engage clinical and regulatory pathways for test development. By advancing non-invasive, accurate adenoma detection, this research directly supports NCI's mission to reduce cancer mortality through improved early detection and screening. [CITE: NCI strategic plan or relevant program announcement if applicable]

---

> **Author's Flags for Attention Before Submission:**
> - **[CITE]** markers appear at 5 locations requiring literature citations (CRC statistics, compliance rates, FIT/Cologuard sensitivity, microbiome-CRC foundational studies, NCI mission statement)
> - **[NEEDS PRELIM DATA]** flags appear at 2 locations: (1) power/sample size justification for Aim 1 enrollment targets; (2) mechanistic rationale for FIT + microbiome non-redundancy in Aim 2
> - **Innovation claim** ("first study to combine microbiome signatures with FIT for adenoma detection") should be verified with a current literature search before submission—this claim is central to the application's novelty argument and must be defensible
> - Consider adding 1–2 sentences on **diversity/equity** in cohort enrollment, as NIH increasingly scrutinizes this in study design
> - The 78% AUC from your pilot is a strength—consider whether space allows one sentence quantifying the gap between your classifier and FIT alone to sharpen the motivation for Aim 2
````

## Assessment
_To be completed by a human reviewer. Do not mark Pass without reading the output._

### Task Achievement
- **Achieved:** [Yes / No / Partial]
- **Notes:**

### Constraint Compliance
- **All constraints respected:** [Yes / No]
- **Violations noted:**

### Failure Modes
- **Failure modes observed:** [None / list]
- **Mitigation effectiveness:**

### Output Format
- **Format correct:** [Yes / No]
- **Deviations:**

## Overall Assessment
- **Recommendation:** PENDING AUTHOR REVIEW
- **Notes:**

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
